CVS Caremark extends tender for Longs

21 September 2008

CVS Caremark Corp has extended the expiration for its tender offer to purchase all of the outstanding common shares of Longs Drug Stores, at a price of $71.50 each in cash, to midnight, New York City time at the end of October 15. All other terms and conditions of the tender offer remain unchanged.

CVS Caremark has received a copy of Walgreen's unsolicited, non-binding expression of interest received by Longs, which is subject to completion of due diligence and regulatory approval. As previously announced (Marketletter September 8), CVS Caremark has entered into a definitive merger agreement with Longs and commenced a cash tender offer of $71.50 per share for its outstanding shares.

Tom Ryan, chief executive of CVS Caremark, commented, "our offer represents a full and fair price for Longs' shares, and we stand firm on our price. Furthermore, the CVS Caremark's offer has cleared all regulatory hurdles and provides certainty of completion to Longs shareholders."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight